Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Specialty Drug Price Increases Start To Resemble The Tortoise, Not The Hare

Executive Summary

Medicare Part B's switch to payments based on average sales price is prompting manufacturers to take smaller, more frequent price increases for specialty drugs

You may also be interested in...



End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP

Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward

End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP

Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward

Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates

Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices

Topics

UsernamePublicRestriction

Register

PS046660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel